Prevalence of High Serum Uric Acid Level in Patients with Chronic Kidney Disease Stage II-V
Keywords:
Uric Acid, Hyperuricemia, Prevalence, Kidney Failure, Chronic Renal DiseasesAbstract
Background: Chronic kidney disease (CKD) has emerged as a significant public health issue affecting millions of individuals of all races and ethnic groups. It's also a major health burden in Nepal. Hyperuricemia is widely established as a risk factor for glomerulosclerosis, interstitial fibrosis, and atherosclerosis. However, reversing and preventing it in CKD will delay the course of chronic renal failure. Therefore, this research was designed to examine the uric acid profile in CKD patients who are receiving conservative therapy to avoid the worsening of CKD.
Methods: The study included a total of 90 CKD patients at stages II-V. The complete history taking, clinical examination, and laboratory testing were done and the data were analyzed using SPSS version 22. The prevalence of hyperuricemia was determined and compared at various stages of CKD.
Results: Among the enrolled patients (n = 90), the majority were male (66%) in gender. The maximum number of patients (44%) were elderly (60-80 years). Hyperuricemia was present in 80% of patients. Among them, two patients were in stage II (7.4±0.42), five in stage IIA (8.8±1.22), 25 in stage IIIB (8.59±1.63), 36 in stage IV (9.21±1.49), and three patients were in stage V (10.70±1.609).
Conclusion: Serum uric acid levels were elevated in various stages of CKD patients. Thus, serum uric acid may be used as a predictive indicator of CKD. However, large-scale cohort research of the Nepalese population is suggested to corroborate the results of this study.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Arun Sharma, Smriti Acharya, Sitaram Khadka, Gaurav Bhandari, Raj Kumar Thapa , Kanchan KC, Suyash Acharya, Suyash Acharya
This work is licensed under a Creative Commons Attribution 4.0 International License.
The author(s) retain the copyright and the full publishing right without restriction under the Creative Commons Attribution 4.0 International License (CC BY 4.0) which allows readers to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, even commercially, provided the work is properly attributed. (https://creativecommons.org/licenses/by/4.0/).
Author(s) grant the non-exclusive publishing right to the Journal of Karnali Academy of Health Sciences (JKAHS). The publishing rights include the rights to publish, reproduce, distribute, include in indexes or search databases or other media in print or online. The JKAHS may require revisions to the manuscript before acceptance for publication or may choose not to publish it based on the judgement of the editors. Further, JKAHS might retract, withdraw, or publish a correction or other notice after publication, if such publication would be inconsistent with the good publication practices and associated guidelines set forth by the COPE (Committee on Publication Ethics) (https://publicationethics.org/core-practices).
More information about the Creative Commons Attribution 4.0 International License can be found in the webpage of Creative Commons (CC) by following the link provided below: https://creativecommons.org/licenses/by/4.0/
